Abstract Library

#4089 Peptide receptor radionuclide therapy is effective for hormonal control of carcinoid syndrome

Introduction: Carcinoid syndrome (CS) is the most common functioning syndrome in neuroendocrine tumors (NET) and manifests in symptoms of flushing, diarrhea and fibrosis. Serotonin, a tryptophan metabolite, is considered the principal hormonal mediator of CS. Peptide receptor radionuclide therapy (PRRT) has established antiproliferative effects in NET, but the clinical and biochemical response to PRRT in CS patients is unknown.

Conference:

Presenting Author: Maas C

Authors: Maas C, Mulders M, Mirzaian M, van den Berg S, Brabander T,

Keywords: carcinoid syndrome, neuroendocrine tumor, peptide receptor radionuclide therapy, serotonin,

#3368 Dose-limiting bone marrow toxicities after Peptide Receptor Radionuclide Therapy are sexually dimorphic

Introduction: Peptide receptor radionuclide therapy (PRRT) can cause dose-limiting toxicities (DLTs) of the bone marrow, liver, and kidneys. It is yet unknown whether women and men are equally at risk for these DLTs.

Conference:

Presenting Author: Minczeles N

Authors: Minczeles N, de Herder W, Konijnenberg M, Feelders R, Brabander T,

Keywords: peptide receptor radionuclide therapy, neuroendocrine tumor, haematological toxicity, sex,

#3213 Hyponatremia and hypernatremia have an opposing effect on overall survival in neuroendocrine tumor patients treated with peptide receptor radionuclide therapy

Introduction: Hypo- and hypernatremia are common electrolyte abnormalities in patients with malignancy and have been independently associated with worse survival outcomes. To date, there is no data on the influence of dysnatremia on patients with neuroendocrine tumors (NET).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Refardt J, Brabander T, Minczeles N, Feelders R, de Herder W,

Keywords: hyponatremia, hypernatremia, survival, PRRT,

#3107 Predicting response after [166Ho]-radioembolization in patients with neuroendocrine tumor liver metastases using neutrophil-to-lymphocyte and thrombocyte-to-lymphocyte ratios

Introduction: Response after treatment with [166Ho]-radioembolization is difficult to predict in patients with NET. Neutrophil-to-lymphocyte ratio (NLR) and thrombocyte-to-lymphocyte ratio (TLR) have been described as prognosticators for response.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Ebbers S

Authors: Ebbers S, Brabander T, Tesselaar M, Hofland J, Barentsz M,

Keywords: PRRT, NET, neuroendocrine tumor, neuroendocrine neoplasm, lutetium-177-dotatate, radioembolization, holmium-166, objective response, NLR, TLR,

#3105 Hematotoxicity of Holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial PRRT

Introduction: In patients with neuroendocrine tumor liver metastases, additional tumor reduction can be achieved by sequential treatment with [166Ho]-radioembolization after peptide receptor radionuclide therapy (PRRT).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Ebbers S

Authors: Ebbers S, Brabander T, Tesselaar M, Hofland J, Barentsz M,

Keywords: PRRT, NET, neuroendocrine tumor, neuroendocrine neoplasm, lutetium-177-dotatate, radioembolization, holmium-166, hematologic toxicity,